

October 1 & 2, 2015
Inn at the Forks
Winnipeg, MB

11th Canadian CLL Research Meeting

Thursday, October 1, 2015

07:30 Breakfast

08:00-08:10 Welcome
Carolyn Owen

SESSION 1: NOVEL THERAPIES

Chair: Cindy Toze

- 08:10-09:10 **KEYNOTE ADDRESS**
The future of CAR T cell therapy
Stan Riddell, Fred Hutchinson Cancer Research Centre, Seattle, WA
- 09:10-09:40 The use of novel agents pre/post allogeneic HSCT in CLL
Jennifer Brown, Dana Farber Cancer Institute, Boston, MA
- 09:40-10:10 Mechanisms of action and resistance of CLL novel agents
Amy Johnson, Ohio State University
- 10:10-10:30 Update on recent trials (Ofatumumab + Akt inhibitor & Rev-Dex upfront trial)
Christine Chen, Princess Margaret Hospital, Toronto
- 10:30-10:40 COFFEE

Potential Targets in CLL for Clinical Trials

Chair: Asish Ghosh

- 10:40-11:00 Ruxolitinib in CLL
David Spaner, Sunnybrook HSC, Toronto, ON
- 11:00-11:20 Lysosomes as potential targets in CLL
Rebecca Dielschneider, CancerCare Manitoba, Winnipeg
- 11:20-11:40 NAMPT as a potential target in CLL
Eric Bouchard, CancerCare Manitoba, Winnipeg
- 11:40-12:10 Axl receptor tyrosine kinase: An attractive therapeutic target in CLL
Asish Ghosh, Mayo Clinic, Rochester, MN
- 12:10-12:30 Identifying novel therapy approaches for development of personalized CLL therapy
Sina Oppermann, Sunnybrook Health Sciences Centre, Toronto
- 12:30-13:30 LUNCH

Thursday, October 1, 2015

SESSION 2: THE WORKSHOPS

Chair: Carolyn Owen

- 13:30-14:15 Allogeneic stem cell transplantation in Canada: Approach to a standardized regimen/indications
Cindy Toze, BCCA, Vancouver
Mitchell Sabloff, Ottawa
- 14:15-15:00 Approach to creating a pan-Canadian database/tissue bank
Brent Zanke,, Ottawa
Alina Gerrie, BCCA, Vancouver
Brent Schacter, CTRnet, Winnipeg
James Johnston, Manitoba CLL database, Winnipeg
- 15:00-15:20 The mutational basis of immune privilege in B cell lymphoma/the\ pathogenic importance of the microenvironment
Christian Steidl, BCCA, Vancouver, BC
- 15:20-15:30 COFFEE

Clinical Utility of Databases

Chair: James Johnston

- 15:30-15:50 17p deletion as a predictive & prognostic biomarker in the era of targeted agents
Inhye Ahn, National Institutes of Health, Bethesda, MD
- 15:50-16:10 Outcome of CLL patients with elevated BMI, diabetes or atopy
Sara Beiggi, Mayo Clinic, Rochester, MN
- 16:10-16:30 Significance of skin cancer diagnoses in the Manitoba CLL cohort
James Johnston, CancerCare Manitoba
- 16:30-16:50 Transformation events in CLL
Sameer Parikh, Mayo Clinic, Rochester, MN
- 16:50-17:00 CLL Patient Advocacy Group Update
Peter Dorfman, Vice-Chair, CLLPAG
- 17:00-1900 POSTERS
Judges: Gerald Marti, Aaron Marshall, Alina Gerrie
Inaugural George Smith Prize for excellence in CLL research
Presented by Donna Simister
- 17:15 DINNER

Friday, October 2, 2015

07:30 Breakfast

SESSION 3: THE CLL MICROENVIRONMENT***Chairs: Wei Ding and Aaron Marshall***08:00-08:30 The kinetics of CLL and influence by novel agents
*Jan Burger, MD Anderson, Houston, TX*08:30-09:00 CLL stroma, a senescent microenvironment
*Wei Ding, Mayo Clinic, Rochester, MN*09:00-09:30 Development and evolution of CLL B cells based on unique structural features of the BCR Ig
*Nicholas Chiorazzi, The Feinstein Institute of Medical Research, Manhasset, NY*09:30-10:00 ZAP70 and CLL cell interactions with the microenvironment
Aaron Marshall, University of Manitoba, Winnipeg

10:00-10:10 COFFEE

SESSION 4: GENETICS/GENOMICS**Chair: David Spaner**10:10-10:30 DNA methylation in CLL
*Chris Oakes, Ohio State University*10:30-10:50 Update on novel techniques for prognostic evaluation of early stage CLL
*Neil Kay, Mayo Clinic, Rochester, MN*10:50-11:10 The emerging role of the UGT2B17 metabolic pathway in CLL progression and resistance
*Eric Allain, Centre de recherche du CHU de Quebec*11:10-11:30 HDAC-repressed microRNA in high risk CLL
*Deepa Sampath, Ohio State University*11:30-11:50 Insights into monoclonal B cell lymphocytosis
*Gerald Marti, National Institutes of Health, Bethesda, MD*11:50-12:10 Polymorphisms in hyaluronan synthase 1 in the prediction of B cell malignancies
*Linda Pilarski, Cross Cancer Institute, Edmonton*12:10-12:30 The landscape of genetic testing for CLL in Canada
Tanya Gillan, BCCA, Vancouver, BC/Adam Smith, Toronto, ON

Friday, October 2, 2015

SESSION 4: GENETICS/GENOMICS (Cont'd)

Chair: David Spaner

- 12:30-12:50 Enhancing sensitivity of lymphoma and CLL to nutrient stress through targeting TRAF1
Tania Watts, University of Toronto
- 12:50-13:10 Tregs in Asian vs. non-Asian CLL patients
Deepesh Lad, BCCA, Vancouver, BC
- 13:10-13:30 Partial reconstitution of normal B cells and humoral immunity in patients with CLL treated with ibrutinib
Clare Sun, National Institutes of Health, Bethesda, MD
- 13:30-13:45 Closing words
- 13:45 LUNCH

Organizing Committee

Dr. C. Owen (Chair), AB

Dr. C Toze, BC

Dr. A. Gerrie, BC

Dr. L. Larratt, AB

Dr. J. Stakiw, SK

Dr. V. Banerji, MB

Dr. M. Seftel, MB

Dr. D. Spaner, ON

Dr. L. Amrein, QC

Dr. S Assouline, QC

Dr. S. Robinson, NS

Dr. K. Tompkins, NL